Loading…
Sectoral / Thematic · DSP Mutual Fund · AMFI code 145453DSP Healthcare Fund
Disclosed for 94 months, Dec 2018 to Sep 2026.
Portfolio value
₹1,243 Cr
up ₹41 Cr vs Mar 2023
- Stocks held
- 25
- up 2 vs Mar 2023
- Top 10 weight
- 66.3%
- of the portfolio in its ten largest
- Cash & debt
- 0.2%
- cash, money market and debt
- Moves this month
- 2 in · 0 out
- added to 10, trimmed 8
DSP Healthcare Fund is an active equity fund in the Sectoral / Thematic category from DSP Mutual Fund. In April 2023 it disclosed 25 stocks worth ₹1,243 Cr, up ₹41 Cr from Mar 2023. Its largest positions were Sun Pharmaceutical Industries Limited (16.2%), Cipla Limited (9.7%), Apollo Hospitals Enterprise Limited (6.8%); the ten largest together made up 66.3% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 69.5% of its equity. Cash and debt stood at 0.2%. Compared with Mar 2023 the fund entered 2 new stocks and exited 0.
Against 229 other Sectoral / Thematic funds
Concentration
91%
Top-10 weight is higher than 91% of peers
Breadth
8%
Holds more stocks than 8% of peers
Cash
3%
Holds more cash than 3% of peers
What these mean: concentration · cash
Holdings in April 2023
Download CSVEvery line the fund disclosed, with the change against Mar 2023. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 16.19% | down 1.09 pts | ₹201 Cr | down ₹6.5 Cr | Trimmed |
| Cipla Limited | 9.73% | down 0.25 pts | ₹121 Cr | up ₹1 Cr | Added |
| Apollo Hospitals Enterprise Limited | 6.76% | up 0.08 pts | ₹84 Cr | up ₹3.8 Cr | Added |
| Procter & Gamble Health Limited | 5.95% | down 0.24 pts | ₹73.9 Cr | down ₹43 L | Trimmed |
| Lupin Limited | 5.82% | up 0.32 pts | ₹72.3 Cr | up ₹6.2 Cr | Added |
| Alkem Laboratories Limited | 5.02% | down <0.01 pts | ₹62.4 Cr | up ₹2 Cr | Added |
| Alembic Pharmaceuticals Limited | 4.91% | up 0.38 pts | ₹61 Cr | up ₹6.6 Cr | Added |
| IPCA Laboratories Limited | 4.51% | down 0.81 pts | ₹56.1 Cr | down ₹7.9 Cr | Trimmed |
| Intuitive Surgical Inc | 3.72% | up 0.45 pts | ₹46.2 Cr | up ₹6.9 Cr | Added |
| Suven Pharmaceuticals Limited | 3.72% | down 0.13 pts | ₹46.2 Cr | down ₹5 L | Held |
| Mankind Pharma Limited | 3.38% | up 3.38 pts | ₹42.1 Cr | up ₹42.1 Cr | New |
| Indoco Remedies Limited | 3.29% | down 0.13 pts | ₹40.9 Cr | down ₹23 L | Trimmed |
| Zydus Lifesciences Limited | 3.20% | down 1.02 pts | ₹39.8 Cr | down ₹11 Cr | Trimmed |
| Vijaya Diagnostic Centre Limited | 3.09% | down 0.22 pts | ₹38.5 Cr | down ₹1.4 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 2.72% | down 1.59 pts | ₹33.8 Cr | down ₹18 Cr | Trimmed |
| Globus Medical Inc | 2.56% | down 0.02 pts | ₹31.9 Cr | up ₹85 L | Added |
| Aarti Drugs Limited | 2.51% | up 0.43 pts | ₹31.3 Cr | up ₹6.2 Cr | Added |
| Abbott Laboratories | 2.30% | up 0.12 pts | ₹28.6 Cr | up ₹2.4 Cr | Added |
| ICICI Lombard General Insurance Company Limited | 2.10% | down 0.05 pts | ₹26.1 Cr | up ₹23 L | Added |
| Syngene International Limited | 2.04% | up 0.19 pts | ₹25.4 Cr | up ₹3.1 Cr | Added |
| Kovai Medical Center and Hospital Limited | 1.82% | up 0.05 pts | ₹22.6 Cr | up ₹1.3 Cr | Added |
| Global X Funds - Global X Genomics & Biotechnology ETF Fund units | 1.61% | down 0.06 pts | ₹20 Cr | down ₹1 L | Held |
| MedPlus Health Services Limited | 1.14% | up 0.10 pts | ₹14.2 Cr | up ₹1.7 Cr | Added |
| Illumina Inc | 1.14% | down 0.17 pts | ₹14.1 Cr | down ₹1.6 Cr | Trimmed |
| Pfizer Limited | 0.46% | up 0.02 pts | ₹5.7 Cr | up ₹43 L | Added |
| Cash, TREPS & receivables | 0.23% | up 0.18 pts | ₹2.9 Cr | up ₹2.3 Cr | Added |
| Taro Pharmaceutical Industries Limited | 0.08% | up 0.08 pts | ₹1 Cr | up ₹1 Cr | New |
What changed, Mar 2023 to Apr 2023
New New positions (2)
- Mankind Pharma Limited3.4% · ₹42.1 Cr
- Taro Pharmaceutical Industries Limited0.1% · ₹1 Cr
Exited Exited (0)
None.
Added Biggest additions
- Intuitive Surgical Incup ₹6.9 Cr (+0.45% pts)
- Alembic Pharmaceuticals Limitedup ₹6.6 Cr (+0.38% pts)
- Lupin Limitedup ₹6.2 Cr (+0.32% pts)
- Aarti Drugs Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Mar 2023, the weight rose most in Healthcare Equipment & Supplies (+0.4 pts) and Retailing (+0.1 pts), and fell most in Pharmaceuticals & Biotechnology (−0.4 pts).
- Healthcare Equipment & Supplies6.0% → 6.4%+0.4 pts
- Retailing1.1% → 1.2%+0.1 pts
- Pharmaceuticals & Biotechnology69.9% → 69.5%−0.4 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Apr 2020 | Apr 2022 | Oct 2022 | Jan 2023 | Mar 2023 | Apr 2023 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 70.7% | 55.4% | 61.4% | 67.6% | 69.9% | 69.5% |
| Healthcare Services | 15.3% | 28.0% | 23.3% | 16.6% | 15.2% | 15.1% |
| Healthcare Equipment & Supplies | 1.6% | 5.5% | 6.4% | 6.6% | 6.0% | 6.4% |
| Pharmaceuticals | 10.1% | 7.1% | 5.6% | 5.8% | 5.7% | 5.7% |
| Insurance | 2.4% | 2.5% | 2.4% | 2.3% | 2.2% | 2.1% |
| Retailing | — | 1.5% | 1.0% | 1.0% | 1.1% | 1.2% |
Allocation in Apr 2023change vs Mar 2023
- Pharmaceuticals & Biotechnology (14)69.5%▼ 0.4 pts
- Healthcare Services (5)15.1%▼ 0.1 pts
- Healthcare Equipment & Supplies (2)6.4%▲ 0.4 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Apr 2023
0.2%
▲ 0.2 pts vs Mar 2023
- Cash alone
- 0.2%
- cash and net receivables
- A year earlier
- 0.6%
- Apr 2022 · now ▼ 0.4 pts
- Last 12 months
- −<0.1% – 4.2%
- lowest to highest · record 28.6% in Dec 2018
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.